Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension
Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension
– On track to announce topline data in Q1 2025 –
2025年第一季度有望宣佈總體數據
– Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension –
將於10月30日舉辦虛擬KOL活動，討論高血壓領域的未滿足需求，以及對lorundrostat在高血壓領域正在進行的關鍵臨床項目進行審查
RADNOR, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced that it has achieved the enrollment target of 261 subjects in the pivotal Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to a standardized background treatment of two or three antihypertensive medications. Additional subjects currently in the screening or the run-in phase for Advance-HTN may be enrolled over the next several weeks. The Company continues to expect to announce topline data in the first quarter of 2025.
賓夕法尼亞州RADNOR，2024年9月25日（環球新聞社）--礦力生物製藥公司（納斯達克：MLYS）是一家臨床階段的生物製藥公司，致力於開發針對高血壓、慢性腎臟疾病（CKD）和其他常見心血管疾病的藥物，這些疾病受到醛固酮失調驅動。今天宣佈，該公司已在關鍵Advance-HTN試驗中完成了261名受試者的招募目標，該試驗評估了lorundrostat作爲附加治療用於未控制高血壓（uHTN）或難治性高血壓（rHTN）時的療效和安全性，當lorundrostat作爲兩種或三種抗高血壓藥物的標準背景治療的附加治療時。目前仍有額外受試者處於Advance-HTN的篩選或試驗期階段，他們可能在接下來的幾周內被納入進來。公司繼續預計將於2025年第一季度宣佈總體數據。
譯文內容由第三人軟體翻譯。
